

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re U.S. Patent of

Takehiko NAKA et al.

Patent No. 5,196,444

Issued: March 23, 1993

Date Allowed: Feb. 25, 1992

Batch No.: A48

Serial No. 07/687,238

Filed: April 18, 1991

For: 1-(CYCLOHEXYLOXYCARBONYLOX-YETHYL 2-ETHOXY-1-[[2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL]METHYL]BENZIMIDAZOLE-7-CARBOXYLATE AND COMPOSITIONS AND METHODS OF PHARMACEUTICAL USE THEREOF

REQUEST FOR CERTIFICATE OF
CORRECTION UNDER 37 C.F.R. §1.322

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Patentee hereby respectfully requests the Commissioner to issue a Certificate of Correction for the above-captioned patent in accordance with the accompanying Form PTO-1050 (submitted in duplicate).

In Column 4, between lines 44 and 45, please insert the following:

--3. Injections

- | | | |
|-----|--|--------|
| (1) | 2-methylthio-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid disodium salt | 10 mg |
| (2) | inositol | 100 mg |
| (3) | benzyl alcohol | 20 mg |
| | one ampoule | 130 mg |

(1), (2) and (3) are dissolved in distilled water for injection to make the whole volume 2 ml, which is filled into an ampoule. The whole process is conducted under sterile conditions.

4. Capsules

CERTIFICATE
OF
CORRECTION
BRANCH
OF
PATENT & TRADEMARK

OCT 10 95

RECEIVED

Talked with Mr. Stephens
on 11-9-95 please delete 1050 Form.

~~Deleted~~

CoSC
~~Handwritten signature~~

- | | | |
|-----|--|--------|
| (1) | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate | 10 mg |
| (2) | lactose | 90 mg |
| (3) | fine crysatalline cellulose | 70 mg |
| (4) | magnesium stearate | 10 mg |
| | one capsule | 180 mg |

(1), (2), (3) and a half of (4) are mixed and granulated. To the granules is added the remainder of (4), and the whole is filled into gelatin capsules.

5. Tablets

- | | | |
|-----|--|--------|
| (1) | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate | 10 mg |
| (2) | lactose | 35 mg |
| (3) | corn starch | 150 mg |
| (4) | fine crystalline cellulose | 30 mg |
| (5) | magnesium stearate | 5 mg |
| | one tablet | 230 mg |

(1), (2), (3), two thirds of (4) and a half of (5) are mixed and granulated. To the granules are added the remainders of (4) and (5), followed by subjecting the granules to compression molding.

6. Injections

- | | | |
|-----|--|--------|
| (1) | 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid disodium salt | 10 mg |
| (2) | inositol | 100 mg |
| (3) | benzyl alcohol | 20 mg |
| | one ampoule | 130 mg |


Patent No. 5,196,444

(1), (2) and (3) are dissolved in distilled water for injection to make the whole volume 2 ml, which is filled into an ampoule. The whole process is conducted under sterile conditions.--

Since this Certificate is needed to correct the mistakes which were the fault of the Patent and Trademark Office, it is believed that no fee is required.

Respectfully submitted,

October 5, 1995
Date


Harold C. Wegner
Reg. No. 25,258

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, DC 20007-5109
Tel: (202) 672-5300

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 5,196,444
DATED : March 23, 1993
INVENTOR(S) : Takehiko NAKA et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Column 4, between lines 44 and 45, please insert following:

-- 3. Injections

(1) 2-methylthio-1-[[2'-(1H-tetrazol-5-yl)biphenyl]methyl]benzimidazole-7-carboxylic acid disodium

10 m

(2) inositol

100 m

(3) benzyl alcohol

20 m

one ampoule 130 m

(1), (2) and (3) are dissolved in distilled water injection to make the whole volume 2 ml, which is filled into an ampoule. The whole process is conducted under sterile conditions.

MAILING ADDRESS OF SENDER:

FOLEY & LARDNER

3000 K Street, N.W., Suite 500
Washington, DC 20007-5109

PATENT NO. 5,196,444

Ne



UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 5,196,444
DATED : March 23, 1993
INVENTOR(S) : Takehiko NAKA et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

4. Capsules

- | | | |
|-----|---|--------|
| (1) | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole carboxylate | 10 mg |
| (2) | lactose | 90 mg |
| (3) | fine crystalline cellulose | 70 mg |
| (4) | magnesium stearate | 10 mg |
| | one capsule | 180 mg |

(1), (2), (3) and a half of (4) are mixed granulated. To the granules is added the remainder of (4) and the whole is filled into gelatin capsules.

5. Tablets

- | | | |
|-----|---|--------|
| (1) | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole carboxylate | 10 mg |
| (2) | lactose | 35 mg |
| (3) | corn starch | 150 mg |
| (4) | fine crystalline cellulose | 30 mg |

MAILING ADDRESS OF SENDER:

FOLEY & LARDNER

3000 K Street, N.W., Suite 500
Washington, DC 20007-5109

PATENT NO. 5,196,444

Ne

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 5,196,444
DATED : March 23, 1993
INVENTOR(S) : Takehiko NAKA et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(5) magnesium stearate 5 g
one tablet 230 mg

(1), (2), (3), two thirds of (4) and a half of (5) mixed and granulated. To the granules are added remainders of (4) and (5), followed by subjecting granules to compression molding. ✓

6. Injections

(1) 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-methyl]benzimidazole-7-carboxylic acid disodium salt

10 mg

(2) inositol

100 mg

(3) benzyl alcohol

20 mg

one ampoule 130 mg

(1), (2) and (3) are dissolved in distilled water for injection to make the whole volume 2 ml, which is filled into an ampoule. The whole process is conducted under sterile conditions.--

MAILING ADDRESS OF SENDER:

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, DC 20007-5109

PATENT NO. 5,196,444

N